# Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Study · id `cardio:ct-nct02480764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02480764](<https://clinicaltrials.gov/study/NCT02480764>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02480764

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 612 participants.

## Technical summary

Registry record NCT02480764. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-27 (actual); primary completion 2017-09-22 (actual). Results posted on 2019-02-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 612 participants (enrolled count; ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Started: 2015-08-27 (actual) (ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Primary completion: 2017-09-22 (actual) (ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Completion: 2017-10-13 (actual) (ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Results first posted: 2019-02-11 (ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02480764, source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02480764-2019-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Azilsartan medoxomil
- Intervention (Drug): Valsartan
- Intervention (Drug): Azilsartan medoxomil Placebo
- Intervention (Drug): Valsartan Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension (`cardio:pubmed-32769878`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4ad710f6411d45f9896a8c44572ff232a595aa4d3ab7ae412131caa388e76a25
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
